for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bayer AG

BAYGn.DE

Latest Trade

65.97EUR

Change

-0.24(-0.36%)

Volume

3,112,510

Today's Range

65.46

 - 

66.93

52 Week Range

52.02

 - 

79.47

As of on the XETRA ∙ Minimum 15 minute delay

Latest Developments

Bayer: FDA Approves Rivaroxaban For Blood Clots Prevention

Oct 14 (Reuters) - BAYER AG <BAYGn.DE>::U.S. FDA APPROVES RIVAROXABAN TO HELP PREVENT BLOOD CLOTS IN ACUTELY ILL MEDICAL PATIENTS.APPROVAL IS BASED ON DATA FROM PHASE III MAGELLAN TRIAL, AND SUPPORTED BY DATA FROM MARINER TRIAL.

Sensyne Health Says Expanded Collaboration Agreement With Bayer

Oct 10 (Reuters) - Bayer AG <BAYGn.DE>::SENSYNE HEALTH - EXPANDS EXISTING COLLABORATION AGREEMENT WITH BAYER TO ACCELERATE DEVELOPMENT OF NEW TREATMENTS FOR CARDIOVASCULAR DISEASE.SENSYNE HEALTH PLC - WILL PARTNER WITH BAYER ON INAUGURAL LIFEHUB PROJECT - DEVELOPING AI ENABLED RADIOLOGY TO ENHANCE PATIENT OUTCOMES.

Bayer And Arvinas Unveil Targeted Protein Degradation Joint Venture

Oct 1 (Reuters) - Arvinas Inc <ARVN.O>::BAYER AND ARVINAS UNVEIL TARGETED PROTEIN DEGRADATION JOINT VENTURE, OERTH BIO.JOHN DOMBROSKY ANNOUNCED AS CEO OF OERTH BIO.BAYER, CO ANNOUNCED THEY HAVE FINALIZED TERMS OF THEIR AGREEMENT TO JOINTLY LAUNCH A NEW COMPANY, OERTH BIO.BAYER AND ARVINAS WILL EQUALLY SHARE GOVERNANCE AND EQUITY OWNERSHIP OF JOINT VENTURE.ARVINAS - OERTH BIO WILL BE SUPPORTED BY INTELLECTUAL PROPERTY,OVER $55 MILLION IN FUNDING FROM BAYER AND TECHNOLOGY AND INTELLECTUAL PROPERTY FROM ARVINAS.

Bayer Wins First EU Approval For High-Precision Cancer Drug

Sept 23 (Reuters) - Bayer AG <BAYGn.DE>::VITRAKVI® (LAROTRECTINIB) RECEIVES FIRST TUMOR-AGNOSTIC APPROVAL IN EU.PRECISION ONCOLOGY TREATMENT VITRAKVI® (LAROTRECTINIB) APPROVED FOR THE TREATMENT OF ADULTS AND CHILDREN WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HAVE A RARE GENOMIC ALTERATION CALLED AN NTRK GENE FUSION.VITRAKVI, WHICH WAS EXCLUSIVELY DESIGNED TO TREAT TRK FUSION CANCER, IS THE FIRST THERAPY IN THE EU WITH A TUMOR-AGNOSTIC INDICATION.IN STUDIES, LAROTRECTINIB DEMONSTRATED AN OVERALL RESPONSE RATE OF 72% INCLUDING 16% COMPLETE RESPONSES, WITH 75% OF PATIENTS STILL ON TREATMENT AFTER ONE YEAR.LAROTRECTINIB SHOWED A FAVORABLE SAFETY PROFILE, WITH THE MAJORITY OF ADVERSE EVENTS (AES) BEING GRADE 1 OR 2; ONLY 3% OF PATIENTS HAD TO STOP THERAPY DUE TO TREATMENT-EMERGENT AES.

Bayer Appoints Marianne De Backer As Head Of Pharmaceuticals Business Development & Licensing

Sept 3 (Reuters) - BAYER AG <BAYGn.DE>::APPOINTS MARIANNE DE BACKER HEAD OF PHARMACEUTICALS BUSINESS DEVELOPMENT & LICENSING AND MEMBER OF EXECUTIVE COMMITTEE.

Bayer Completes Sale Of Coppertone To Beiersdorf

Sept 2 (Reuters) - Bayer AG <BAYGn.DE>::BAYER ANNOUNCED TODAY COMPLETION OF SALE OF COPPERTONE™ BRAND TO BEIERSDORF FOR A PURCHASE PRICE OF 550 MILLION U.S. DOLLARS.

Bayer To Sell Its Animal Health Business Unit To Elanco For $7.6 Bln

Aug 20 (Reuters) - Bayer Ag <BAYGn.DE>::BAYER TO SELL ITS ANIMAL HEALTH BUSINESS UNIT TO ELANCO FOR 7.6 BILLION U.S. DOLLARS.DIVESTMENT IS EXPECTED TO BE CONCLUDED IN MID-2020.BAYER INTENDS TO EXIT ITS STAKE IN ELANCO OVER TIME.

Bayer: Lamb Trial, Initially Slated For Sept In St. Louis City, Postponed

Aug 9 (Reuters) - Bayer AG <BAYGn.DE>::SPOKESMAN SAYS LAMB TRIAL, INITIALLY SLATED FOR SEPT IN ST. LOUIS CITY, HAS BEEN POSTPONED.

Bayer Is Said To Seek $8 Bln Roundup Cancer-Claim Settlement - Bloomberg

Aug 9 (Reuters) - :BAYER IS SAID TO SEEK $8 BILLION ROUNDUP CANCER-CLAIM SETTLEMENT - BLOOMBERG.

Elanco Animal Health Aiming To Reach Agreement As Soon As Next Week To Combine With Bayer's Animal-Health Unit- Bloomberg

Aug 7 (Reuters) - :ELANCO ANIMAL HEALTH IS AIMING TO REACH AN AGREEMENT AS SOON AS NEXT WEEK TO COMBINE WITH BAYER'S ANIMAL-HEALTH UNIT - BLOOMBERG REPORTER ON TWITTER.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up